Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Tau
 More »

  • Fluorescence Lifetime Assays
    FLT (also referred to as tau or τ) is the average time between excitation of a fluorophore and its return to ground energy state. In simple systems, fluorescence intensity decays ...
    5-15-2013
  • Alzheimer's: Lilly Investment Signals R&D Shift
    (PET) tracers, both intended to image tau (or neurofibrillary) tangles in the brain, ... on incorporating the tracer technologies into its anti-amyloid and anti-tau R&D programs. ...
    4-17-2013
  • StemCells Receives $19.3M from CIRM to Fund Alzheimer's Drug
    According to the firm, these results did not require reduction in beta amyloid or tau that accumulates in the brains of patients with Alzheimer's disease and account for the ...
    4-11-2013
  • Merck and Luminex Ink Alzheimer's CDx Deal
    the xMAP® technology to measure concentrations of two candidate biomarkers (Aβ42 and t-tau) in cerebrospinal fluid samples from patients with mild cognitive impairment (MCI). ...
    3-13-2013
  • Dundee Reinforces Faith in TauRx' AD Drug with Additional $10...
    colleagues, including the discovery of the Tau protein as the main constituent of the Tangle pathology of Alzheimer's disease (Tau tangles), the development of the first Tau ...
    3-5-2013
  • Zapping Pathological Proteins in Alzheimer's
    AC Immune Takes Aim at Misfolded Abeta and Tau, as Firm Eyes Disease Prevention AC ... It is attacking amyloid beta (Abeta) oligomers and tau tangles, the key misfolded proteins ...
    3-1-2013
  • Targeting Tau Protein Release Offers Hope for Alzheimer's Patients
    Researchers from King's College London say that neuronal activity can stimulate tau ... known biological signaling molecules increases the release of tau into the culture medium. ...
    2-15-2013
  • Dyax Makes Latin American HAE Drug Deal
    Likewise, back in June of 2010, it made another strategic partnership with Defiante Farmaceutica, a subsidiary of the pharmaceutical company Sigma-Tau, to develop and commercialize ...
    1-31-2013
  • Merck Serono Launches IT Services Company
    founded last September ; Asceneuron, focused on the development of therapies for the treatment of Alzheimer's disease and Tau protein-related pathologies, and founded in October. ...
    1-15-2013
  • Soligenix Regains Rights to Ill-Fated Oral BDP
    rights to orBec (oral beclomethasone 17.21-dipropionate) from Sigma-Tau Pharmaceuticals. ... In July 2011, Sigma-Tau inked a commercialization deal for orBec that included a $5 ...
    12-27-2012
  • Fast Forward, Ezose Partner on MS Biomarker Discovery
    Ezose has established collaborations with Merck, Sigma-Tau, and Hirosaki University. Fast Forward will pay Ezose Sciences up to $390,000 in support of a collaboration focused on ...
    10-24-2012
  • Prizes and Quackery Dominate iPS Cell News
    ... changes in the amount and form of tau protein, confirming differences in the ... Currently, she said, the company's two programs, its anti-tau antibody program and ...
    10-19-2012
  • Elan to Cut Loose Its Discovery Subsidiary
    ... develop antibodies that target the aberrant, self-propagating forms of alpha-synuclein, and the Alzheimer's disease research is focused on developing anti-tau protein antibdodies. ...
    8-13-2012
  • New Hope for Alzheimer's Disease
    ... fluid (CSF) analysis of phosphorylated tau protein and Ab24, and to further develop ... cells and the neurofibriliary tangles (tau protein) formed inside the cells are the ...
    8-1-2012
  • Genentech Taps AC Immune in Second Alzheimer Drug Development...
    to its anti-Tau antibodies for Alzheimer disease and other neurodegenerative diseases. ... collaboration. "The addition of this anti-Tau program to our CNS pipeline complements ...
    6-18-2012
  • More »

    Journal Articles

  • Feasibility and Acceptability of Clinic-Based Telepsychiatry...
    Jenny Chong, Francisco Moreno
    Telemedicine and e-Health
    services through a video Webcam (WEB) (n=80) or to treatment as usual (TAU) (n=87). ... TAU patients received their care from their providers. Acceptability was assessed by ...
  • Long-Term Culture of Mouse Embryonic Stem Cell-Derived Adherent...
    Mirian A.F. Hayashi, Juliano R. Guerreiro, Antonio C. Cassola, Nelson F. Lizier, Alexandre Kerkis, Antonio C.M. Camargo, Irina Kerkis
    Tissue Engineering, Part C: Methods
    medium protein, Tau, neuronal nuclei marker, gamma-aminobutyric acid, and 5-hydroxytryptamine, were confirmed in these cells maintained during 3 months under several splitting. ...
  • Neural Cell Differentiation In Vitro from Adult Human Bone Marrow...
    Xiaoxiao Long, Marie Olszewski, Wei Huang, Morris Kletzel
    Stem Cells and Development
    Some cells were positive for early neural markers Nestin and ß-tubulin III. Cells expressing mature neuronal markers (NF, NeuN, Tau, Nurr1, GABA, oligodendryte GalC, and glial ...
  • Neuroinflammation in Delirium: A Postmortem Case-Control Study
    Barbara C. van Munster, Eleonora Aronica, Aeilko H. Zwinderman, Piet Eikelenboom, Colm Cunningham, Sophia E.J.A de Rooij
    Rejuvenation Research
    Human leukocyte antigen-DR (HLA-DR) and CD68 cell count and glial fibrillary acidic protein (GFAP), interleukin-1ß (IL-1ß), IL-6,ß-amyloid, and tau protein immunoreactivity were ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll